NSEDCP
RVNC

NJ State Employees Deferred Compensation Plan’s Revance Therapeutics, Inc. RVNC Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,900
Closed -$54.4K – 462
2024
Q4 		$54.4K Hold
17,900
– – 0.01% 454
2024
Q3 		$92.9K Hold
17,900
– – 0.01% 457
2024
Q2 		$46K Hold
17,900
– – 0.01% 461
2024
Q1 		$88.1K Hold
17,900
– – 0.01% 459
2023
Q4 		$157K Hold
17,900
– – 0.02% 452
2023
Q3 		$205K Hold
17,900
– – 0.03% 425
2023
Q2 		$453K Hold
17,900
– – 0.07% 296
2023
Q1 		$577K Hold
17,900
– – 0.09% 243
2022
Q4 		$330K Hold
17,900
– – 0.05% 349
2022
Q3 		$483K Buy
+17,900
New +$363K 0.08% 251

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's RVNC Position: Q1 2025 in Review

NJ State Employees Deferred Compensation Plan sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 17,900 shares — an estimated $54.4K sold.

NJ State Employees Deferred Compensation Plan first reported a position in RVNC in Q3 2022 and held it in 10 quarters. The position peaked at $577K in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • NJ State Employees Deferred Compensation Plan reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • NJ State Employees Deferred Compensation Plan sold 17,900 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $54.4K.
  • NJ State Employees Deferred Compensation Plan first reported a position in Revance Therapeutics, Inc. in Q3 2022 and held it in 10 quarters.
  • NJ State Employees Deferred Compensation Plan's Revance Therapeutics, Inc. position peaked at $577K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q1 2025, filed 9 May 2025.